Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443196 · ClinicalTrials.gov registry record · Phase 2
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
A Phase 2 study of Ovarian Neoplasms and Adenocarcinoma, sponsored by Pierian Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00443196 is a Phase 2 study of Ovarian Neoplasms and Adenocarcinoma that has completed, run by Pierian Biosciences. The registered enrollment target is 150 participants, below the 364-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00443196, a Phase 2 study of Ovarian Neoplasms and Adenocarcinoma, has completed, sponsored by Pierian Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
2.0 Study Objectives: 2.1 To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients for first-line treatment. 2.2 To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients in a third-line, refractory treatment setting (exclusive of anti-VEGF)
Conditions Studied
Interventions
- PROCEDURE MiCK Assay
Study Locations (1)
Georgia
- Southeastern Gynecologic Oncology - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00443196
The ClinicalTrials.gov registry entry for NCT00443196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 364-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (59% lower). The listed sponsor is Pierian Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ovarian Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which MiCK Assay is the first listed.
NCT00443196 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT00443196 about?
NCT00443196 is a clinical study titled "Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas". 2.0 Study Objectives: 2.1 To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients for first-line treatment. 2.2 To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients in a third-line, refractory treatment setting (exclusive of ...
What is the current status of trial NCT00443196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2006-03. Estimated completion is 2010-09.
What conditions does trial NCT00443196 study?
This clinical trial studies the following conditions: Ovarian Neoplasms, Adenocarcinoma, Peritoneal Neoplasms, Fallopian Tube Neoplasms.
What interventions are being tested in trial NCT00443196?
The interventions under investigation include: MiCK Assay (PROCEDURE).
Who is sponsoring clinical trial NCT00443196?
This trial is sponsored by Pierian Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00443196 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Vigil for Participants With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
COMPLETED · Phase 2
-
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.